Pfizer has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of ShangAhai Fosun Pharmaceutical, for the development, manufacturing and commercialisation of YP05002.  YP05002 is a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase I development for chronic weight management.  “We look forward to contributing our expertise and […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!